Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the availability of Liraglutide for patients with type 2 diabetes; and what steps his Department is taking to ensure that patients with a clinical need for GLP-1 agonists are able to access appropriate treatment when first-line options are unsuitable.

One brand of liraglutide, Victoza, was discontinued in December 2024, although liraglutide injections remain available from other suppliers, who can support the full demand of the United Kingdom.

The Department was aware of supply issues with GLP-1 receptor agonists (GLP-1 RAs), including liraglutide, which have now been resolved. During this time, the Department worked intensively with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others in the supply chain to resolve these issues. We continue to monitor the supply of GLP-1 RAs closely to ensure these medicines remain available for patients.